×

Compositions and Methods for Targeted Immunomodulatory Antibodies and Fusion Proteins

  • US 20130039911A1
  • Filed: 03/04/2011
  • Published: 02/14/2013
  • Est. Priority Date: 03/05/2010
  • Status: Active Grant
First Claim
Patent Images

1. A molecule comprising a targeting moiety fused with an immunomodulatory moiety, wherein:

  • (a) the targeting moiety specifically binds a target molecule, and(b) the immunomodulatory moiety specifically binds to a molecule selected from;

    (i) Transforming growth factor-beta (TGF-β

    );

    Transforming growth factor-beta receptor (TGF-β

    R);

    Programmed death-1 ligand 1 (PD-L1;

    B7-H1) or Programmed death-1 ligand 2 (PD-L2;

    B7-DC);

    Programmed death-1 (PD-1);

    Receptor activator of nuclear factor-κ

    B ligand (RANKL);

    or Receptor activator of nuclear factor-κ

    B (RANK); and

    (ii) 4-1BB (CD137);

    4-1BB ligand (4-1BBL;

    CD137L);

    OX40 (CD134;

    TNR4);

    OX40 ligand (OX40L);

    glucocorticoid-induced tumor necrosis factor receptor family-related gene (GITR;

    AITR);

    GITR ligand (GITRL);

    HVEM;

    LIGHT;

    CD27;

    or CD70.

View all claims
  • 2 Assignments
Timeline View
Assignment View
    ×
    ×